Pricing Log in Create free account

Adaptimmune Therapeutics PLC (ADAPY) vs Neuphoria Therapeutics Inc. (NEUP)

Adaptimmune Therapeutics PLC and Neuphoria Therapeutics Inc. are both Biotechnology companies. Adaptimmune Therapeutics PLC and Neuphoria Therapeutics Inc. are of similar size ($15.0M and $14.6M). Neuphoria Therapeutics Inc. grew revenue faster over the last twelve months: 3,535.1% against −54.0%. Neuphoria Therapeutics Inc. has the higher net margin (0.00% vs −262.5%) and the lower return on invested capital (−232.7% vs 0.00%). Across the 17 metrics below, Neuphoria Therapeutics Inc. leads on 10 and Adaptimmune Therapeutics PLC on 7.

Valuation

Metric ADAPY NEUP Biotechnology median
P/E n/m n/m 10.60
P/S 0.08 0.79 9.40
P/B n/m 0.50 2.13
Price to free cash flow n/m n/m 25.18
EV/EBITDA n/m 0.39 0.66
EV/Sales 0.08 (0.42) 9.02
Earnings yield (3,250.00%) (180.00%) (32.88%)
Free cash flow yield (3,648.13%) (99.13%) (23.13%)

Profitability

Metric ADAPY NEUP Biotechnology median
Gross margin 94.81% 0.00% 68.51%
Operating margin (427.75%) 0.00% 0.00%
Net margin (262.46%) 0.00% 0.00%
Free cash flow margin (294.49%) 0.00% 0.00%
Return on equity (1,349.52%) (61.70%) (51.96%)
Return on assets 0.00% (46.95%) (46.06%)
Return on invested capital 0.00% (232.67%) 0.00%

Growth

Metric ADAPY NEUP Biotechnology median
Revenue growth (TTM) (53.99%) 3,535.05% 6.76%
EPS growth (last fiscal year) 142.86% (1,230.43%) 29.88%
Revenue growth, 5-year CAGR 8.40% 19.07% 9.75%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric ADAPY NEUP Biotechnology median
Debt to equity (0.36) 0.00 0.00
Current ratio 1.52 27.85 4.97
Net debt to EBITDA 0.47 1.26 1.01

Dividend

Metric ADAPY NEUP Biotechnology median
Dividend yield — — 0.41%
Payout ratio — — —

Size

Metric ADAPY NEUP Biotechnology median
Market cap 14.55m 14.99m 161.82m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack